<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3815">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609488</url>
  </required_header>
  <id_info>
    <org_study_id>SJ-859x</org_study_id>
    <nct_id>NCT04609488</nct_id>
  </id_info>
  <brief_title>Surfactant Levels in the Lungs of COVID-19 Patients</brief_title>
  <official_title>An Exploratory Study to Assess Surfactant Levels in COVID-19 Patients Who Will be on Ventilatory Support Due to Severe Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NAME of STUDY: Surfactant levels in the lungs of COVID-19 patients BACKGROUND&#xD;
&#xD;
        -  Infection with SARS-CoV-2 may induce respiratory failure.&#xD;
&#xD;
        -  COVID-19 associated respiratory failure may require ventilatory support.&#xD;
&#xD;
        -  SARS-CoV-2 uses alveolar type II cells for virus replication.&#xD;
&#xD;
        -  Alveolar type II cells are responsible for surfactant production and lack of surfactant&#xD;
           causes respiratory failure in preterm neonates.&#xD;
&#xD;
        -  Lack of surfactant may play role for respiratory failure in COVID-19 patients DESIGN&#xD;
           Exploratory prospective study design without therapeutic intervention of any kind. Lung&#xD;
           fluid will be donated as part of standard care procedures.&#xD;
&#xD;
      HYPOTHESIS Surfactant is measurable in tracheal secretions by mid-infrared FTIR spectroscopy&#xD;
      determined surfactant spectra. Surfactant is reduced in COVID-19 patients requiring&#xD;
      ventilator support as compared to non- COVID-19 patients. Dysfunctional surfactant in&#xD;
      COVID-19 patients regain its function when respiratory function improves.&#xD;
&#xD;
      POPULATION Main population is patients with COVID-19 pneumonia that requires ventilatory&#xD;
      support.&#xD;
&#xD;
      OUTCOME MEASURES Primary outcome is the level of surfactant in lung fluid as obtained by&#xD;
      tracheal suction.&#xD;
&#xD;
      SAMPLE SIZE In total 30 patients will be included: twenty COVID-19 patients and 10&#xD;
      non-COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Surfactant</measure>
    <time_frame>Two years</time_frame>
    <description>The primary outcome is surfactant levels in lung fluid</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>To Assess Surfactant Levels in Lung Fluid</condition>
  <arm_group>
    <arm_group_label>COVID</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non-COVID</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Surfactant assessment</intervention_name>
    <description>To determine surfactant levels in lung fluid</description>
    <arm_group_label>COVID</arm_group_label>
    <arm_group_label>non-COVID</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tracheal fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients are COVID-19 patients requiring ventilatory support by mechanical&#xD;
        ventilation as well as Non-COVID-19 patients requiring ventilatory support by mechanical&#xD;
        ventilation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients positive for coronavirus 2 (SARS-CoV-2) AND&#xD;
&#xD;
          2. Respiratory failure requiring mechanical ventilation support OR respiratory failure&#xD;
             requiring oxygen supplementation AND&#xD;
&#xD;
          3. Age &gt; 18 years AND&#xD;
&#xD;
          4. Permission from next of kin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inability to obtain TS or BL as determined by clinical judgement by responsible clinician.&#xD;
        Patients with known surfactant dysfunction (such as mutations in the SFTPB or ABCA3 gene).&#xD;
        Imminent expected death within 24 hours. Stage 4 severe chronic kidney disease or requiring&#xD;
        dialysis. Liver failure. Anticipated transfer to another hospital within 72 hours.&#xD;
        Participation in another study which in the opinion of the investigator would prevent&#xD;
        enrollment for safety purposes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Henning B Nielsen</last_name>
    <phone>004531365332</phone>
    <email>henningbay@hotmail.com</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zealand University Hospital</investigator_affiliation>
    <investigator_full_name>Henning Bay Nielsen</investigator_full_name>
    <investigator_title>MD DMSci adj Professor specialist consultant Anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

